There are well-documented racial disparities in outcomes for African American patients with clear cell renal cell carcinoma (ccRCC). Despite a dramatic improvement in overall survival in white patients since the advent of targeted therapy, survival for African Americans with advanced ccRCC has not changed. There is little known about potential racial differences in tumor biology of ccRCC.
Supplemental content at jamaoncology.com R enal cell carcinoma (RCC) is the eighth most commonly diagnosed cancer in the United States. It accounts for nearly 64 000 new cancer cases and over 13 000 deaths per year in the United States alone. 1 Multiple studies from the pretargeted therapy era demonstrate that African American patients with RCC have inferior overall survival compared with white patients regardless of age, sex, stage, histologic subtype, or surgical treatment. [2] [3] [4] Despite this documented survival disparity, there is no data examining genomic or transcriptomic differences of clear cell RCC (ccRCC) in African American patients vs white patients. The last decade has produced a wealth of knowledge about the molecular drivers of RCC, including the comprehensive molecular characterization of ccRCC by The Cancer Genome Atlas (TCGA). 5 A hallmark event in the development of ccRCC is loss of heterozygosity of the von Hippel-Lindau (VHL) tumor suppressor gene. VHL inactivation occurs at a rate of 52% to 82% in sporadic ccRCC 5 and leads to stabilization of the α subunit of the hypoxia-inducible factor (HIF) family of transcription factors. Stabilization of HIFα subunits results in their heterodimerization with HIFβ subunits and a transcriptionally active complex whose target genes are intimately involved in tumor angiogenesis. The vascular endothelial growth factor (VEGF) pathway in particular is a key transcriptional HIF target and is targeted by a number of the currently US Food and Drug Administration-approved therapies. In addition, several other genes, such as PBRM1, SETD2, and BAP1, are also mutated in ccRCC patient tumors. 6 Herein, we investigate potential genetic differences in ccRCC that are associated with race.
Methods
The Cancer Genome Atlas and Validation Data and Analysis RNA sequencing, somatic mutation, and copy number data from the TCGA kidney clear cell (KIRC) data set were downloaded from the publically available TCGA data portal (https: //tcga-data.nci.nih.gov/tcga/), and somatic mutation data was downloaded from an independent and publicly available data set from Peña-Llopis et al 6 (GSE25540 data set).
The TCGA RNaseq data set was log2 transformed and median-centered. Two-class significance analysis of microarrays (using 2-fold change and false discovery rate = 0) was performed to generate race-specific gene lists. 7 The significant genes and corresponding fold changes as determined by significance analysis of microarrays were analyzed by Ingenuity Pathway Analysis (Ingenuity Systems) for predicted pathway activation and/or inhibition. Gene Set Enrichment Analysis (Broad Institute) was performed comparing ccRCC tumors from African American patients vs white patients (ethnicity defined by the TCGA) against Molecular Signature Database c2.all.v4.0. The mutations in the 9 most commonly mutated genes-VHL, PBRM1, SETD2, KDM5C, PTEN, BAP1, MTOR, TP53, and PI3KCA 7 -were analyzed between African American patients and white patients. Patients were then classified into the previously described RNA subtypes of ccRCC-ccA and ccB-based on patterns of differential gene expression using prediction analysis of microarray.
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Statistical Analysis
Differences in somatic mutation rates by race were compared using χ 2 or Fisher exact test where applicable. Fisher exact test was used to compare prevalence of the ccA and ccB molecular subtypes between races.
Results
We first investigated whether there are racial differences in the mutational spectrum of ccRCC tumors comparing data from African American patients (n = 19) and white patients (n = 419) from the TCGA ccRCC KIRC data set. Overall, 175 of 351 (50%) white patients had VHL mutations, whereas 2 of 12 (17%) African American patients had VHL mutations (P = .04) ( Figure 1A ) (eTable 1 in the Supplement). In contrast, there were no racial differences in the mutational frequency of other TCGA KIRC-defined significantly mutated genes ( Figure 1A ) (eTable 1 in the Supplement). These results were validated for VHL, PBRM1 and BAP1 in an independent data set verifying the lower prevalence of VHL mutations in African American patients ( Figure 1B ) (eTable 1 in the Supplement) 6 . Given the lower frequency of VHL mutations in African American patients, we investigated the RNA expression of the VEGF ligands and VEGF receptors to evaluate for downstream effects of VHL loss. In the TCGA KIRC data set, 419 white patients and 19 African American patients were available for analysis. In the TCGA data set, African American patients had significantly lower expression of the VEGFA ligand (eFigure 1A in the Supplement), as well as the FLT-1 (VEGFR1) and KDR (VEGFR2) receptors (eFigure 1B in the Supplement). Furthermore, significance analysis of microarrays and subsequent ingenuity pathway analysis of upstream regulators predicted that numerous genes associated with HIF (EPAS1, HIF1A, ARNT, and CREB1) transcriptional regulation were up-regulated in white patients (eTable 2 in the Supplement). Finally, several VEGF and HIF signatures were negatively enriched in African American patients as determined by Gene Signature Enrichment Analysis (eFigure 3 and eTable 3 in the Supplement). In
Key Points
Question Are there genomic differences between clear cell renal cell carcinomas (ccRCC) that arise in African American patients and white patients that may contribute to the disparity in survival outcomes observed between races?
Findings Using data from the The Cancer Genome Atlas clear cell kidney project, we found that African American patients have a significantly lower rate of mutations of the von Hippel-Lindau tumor suppressor gene, as well as decreased hypoxia-inducible factor activation. In addition, African American patients are enriched for a previously defined RNA subtype (ccB) that is associated with worse survival outcomes.
Meaning There are distinct racial differences in the biology of ccRCC tumors that may partially explain the well-documented racial disparity in survival outcomes of African American patients with advanced ccRCC.
aggregate, these findings indicate distinct differences in the biology of ccRCC in African American patients compared with white patients and suggest that ccRCC in African American patients may be less dependent upon HIF and VEGF signaling.
Clear cell renal cell carcinoma is a heterogenous disease that can be classified into 2 distinct molecular subtypes, ccA and ccB, 8 with the ccB subtype associated with a worse survival. 8 (Figure 2A ) (eFigure 3 in the Supplement) and in general had high correlation to the ccB centroid ( Figure 2B ). This predominance of the ccB subtype in African American patients and its association with worse survival suggests that the intrinsic biology of ccRCC in African American patients may contribute to their welldocumented worse survival outcomes.
Discussion
This is the first report to our knowledge to examine genomic differences between ccRCC in African American patients vs white patients. Our results indicate that ccRCC tumors from African American patients exhibit a lower rate of VHL mutation and a correspondingly lower level of HIF and VEGF pathway activation. We therefore postulate that a significantly larger proportion of tumors from African American p at i e nt s m ay h ave a H I F-i n d e p e n d e nt a n d V E G F- 
MTOR ( that there are also a host of other potential factors (eg, access to health care, time to diagnosis, and appropriate treatment) that likely contribute to the racial disparities seen in advanced ccRCC. Nonetheless, the results presented herein provide insight into the potential role that genomic variation plays in the disparity observed between races. Finally, why African American patients with ccRCC have less frequent VHL mutations is unclear. One possibility is that the development of ccRCC in African Americans may have a different etiology. For example, patients with end-stage renal disease have a higher incidence of RCC than the general population, 11 and ccRCC tumors developing in patients with end-stage renal disease have lower rates of 3p loss or VHL mutation. 12, 13 Given higher rates of end-stage renal disease in
African Americans (likely a consequence of a higher incidence and earlier onset of hypertension), 14 it is plausible that the lower rate of VHL mutation in ccRCC tumors from African Americans may be the result of increased rates of end-stage renal disease. Comprehensive population-based studies will be needed to define correlations between race and etiologic heterogeneity.
Conclusions
Despite an impressive improvement in overall survival in white patients since the advent of VEGF pathway-targeted therapy, the survival for African American patients with advanced ccRCC has not changed. We present evidence of distinct differences in tumor biology between African American patients and white patients that would predict for less responsiveness to VEGF-targeted therapy. While this is a plausible biologic explanation for the lack of improved survival in African American patients, it is likely that disparities in health care delivery contribute to survival differences as well.
